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Ex vivostudieshave suggested thathigh dose protonpump inhibitors (PPI)may have negative inotropic effects
in myocardial tissue.We sought to investigate this concept in a real-world clinical setting. In this case series,
we enrolled critically ill patients in the coronary and cardiothoracic intensive care units who had a preexisting
pulmonary artery (PA) catheter in place for hemodynamic monitoring and were on a PPI for prespecified
clinical indications. Hemodynamic measurements were made at baseline and then at 15 minute intervals for
1 hour after PPI administration. A total of 18 patients were evaluated; 72% were male with a mean age of
59.9 years. A total of 9 patients were evaluated on 2 consecutive days, yielding 26 patient-exposures to the
medication. The majority of patients (72%) were receiving 1 or more inotropic agents (n= 6), a vasopressor
(n= 4), or both (n= 4). When compared to baseline values, there was no significant change in mean arterial
pressure (baseline 80 ± 11 mm Hg), heart rate (87 ± 11 bpm), or Fick cardiac index (2.7 ± 1.8 L/min/m2).
Mean PA pressure did decrease transiently at 45 minutes following PPI administration (28.5 ± 7.7 mm Hg at
baseline vs 26.5 ± 7.5 mm Hg, P = 0.017), but is unlikely to be of clinical significance. In conclusion, these
data suggest that IV PPIs do not immediately impact important hemodynamic parameters and are likely safe
in a high-risk intensive care setting.
Introduction
Proton pump inhibitors (PPIs) are one of the most widely
used medications in the United States. The mechanism of
action of PPIs involve inhibition of the H+/K+ adenosine
triphosphatase (ATPase; ie, proton pump), which is the
final step in the acid secretion pathway in gastric tissue. The
H+/K+ ATPase has also been isolated in myocardial and
vascular smooth muscle cells. Ex vivo data suggest that in
myocardial tissue, this enzyme may regulate homeostasis
of H+ and K+, and its suppression could cause cellular
acidosis, interfere with Ca+ responsiveness in the muscle
cells, and thereby depress myocardial contractility.1 It is not
clear if the negative inotropic effect observed in these in
vitro studies translates into clinically relevant consequences
in acutely ill patients. We accordingly sought to evaluate the
acute hemodynamic impact of PPI administration in these
patients.
Methods
After obtaining University of Michigan institutional review
board approval, we evaluated patients in the coronary and
cardiothoracic intensive care units between October 2007
and January 2008. Patients included were receiving an
intravenous (IV) PPI for an approved indication (gastroe-
sophageal reflux, prior gastrointestinal ulcer disease, high
risk for gastritis) and had a pulmonary artery (PA) catheter
in place. The decision to place a PA catheter was made
by the primary team, independent of and prior to study
enrollment. Patients were excluded if they were hemody-
namically unstable within 12 hours of the index PPI dose,
required rapid titration of vasopressor or inotropic agents,
or had an acute change in oxygenation status. Informed
consent was obtained from the patient directly or from an
official patient designate.
Hemodynamic data were obtained prior to, and then
15, 30, 45, and 60 minutes after a PPI was administered.
In all cases, 40 mg of pantoprazole was given as an IV
injection per unit protocol. Data collected included heart
rate (HR), blood pressure (BP), pulse oximetry, right
atrial pressure, PA pressure, pulmonary capillary wedge
pressure if available, pulmonary artery oxygen saturation,
and thermodilution cardiac output when available. Mean
arterial pressure (MAP) and mean PA pressures were
calculated for each time point. Complete blood count,
comprehensive metabolic profile, height, and weight were
recorded the day of study participation. From these data,
a Fick cardiac output and index were calculated.2 Other
data recorded included concurrent medications and doses,
presence of diabetes, chronic kidney disease (creatinine
>1.5 mg/dL), hypertension, and liver failure. A paired t test
was used to compare each value of the measured variables
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Case Reports continued
to baseline values. Data are presented as mean± standard
deviation. A P value of <0.05 was considered significant.
Results
A total of 18 patients were evaluated; 72% were male with
a mean age of 59.9 years. Each patient was evaluated
following 1 or 3 doses of an IV PPI on separate consecutive
days, depending on the clinical course, for a total of 26
patient-exposures to this medication. Patients had been
assigned to an intensive care setting for a variety of clinical
indications; 4 patients were postoperative following mitral
or tricuspid valve repair, 5 patients had recent coronary
artery bypass grafting, 4 patients had acute type A aortic
dissection (2 of whom had recent aortic repair), and 5
patients had nonischemic or ischemic cardiomyopathy and
were awaiting transplant or left ventricular assist device
implantation. The majority of patients (72%) were receiving
1 or more inotropic agents (n = 6), a vasopressor (n = 4), or
both (n = 4) at the time of evaluation. Comorbid conditions
in this population included hypertension (n = 12), diabetes
(n= 4), and chronic kidney disease (n = 6). A total of 6
patientsrequired mechanical ventilationand 3 patientswere
on continuous hemodialysis (Table).
When compared to baseline values, there was no
significant change in systemic blood pressure or cardiac
index (Figure). Similarly, the mean HR at baseline (87 ±
Table 1. Baseline Demographic and Clinical Characteristics of All Patients
Evaluated
n= 18
Age (mean±SD; years) 59.9± 16
Gender n (%) male 13 (72.2%)
Indication for ICU and PA cathetermonitoring, n (%)
Postoperative valve surgery 4 (22.2%)
Postoperative CABG 5 (27.7%)
Type A dissection 4 (22.2%)
Cardiomyopathy 5 (27.7%)
Concurrent medications, n (%)
Inotropic agents 6 (33.3%)
Vasopressors 4 (22.2%)
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Figure 1. Mean arterial pressure and Fick cardiac index values for 1 hour
following IV PPI administration (the data points in blue reflect mean
arterial pressure and the data points in maize reflect cardiac index).
17 bpm) did not change significantly in the hour following
IV PPI administration. Baseline right atrial pressure
(11.5 ± 4.2 mm Hg) and pulse oximetry (96.2%± 2.2%)
values did not change significantlyafter drug administration
(P = not significant for all time points). Mean PA
pressure did decrease transiently at 45 minutes following
PPI administration (28.5 ± 7.7 mm Hg at baseline vs
26.5± 7.5 mm Hg, P = 0.017) but this decrease is unlikely
to be of clinical significance.
Discussion
Proton pump inhibitors are commonly used medications in
the intensive care setting. The safety of these medications
in patients with intrinsic cardiac disease has not been well
studied. Their use accounts for a large portion of the net
pharmaceutical expenditures in the U.S.3 In the inpatient
and intensive care unit settings, these drugs are commonly
used in oral and intravenous formulations as prophylaxis
against stress-induced gastritis, ulcers, and gastrointestinal
bleeding in high-risk patients.4 Proton pump inhibitors may
also be a particularly important intervention after cardiac
surgery.5
Schillinger et alhave evaluated the effects of PPIs
(specifically pantoprazole) on myocardial tissue specimens
from humans and rabbits.1 Human tissue was derived
from 8 patients undergoing heart transplantation (failing
ventricular tissue) and 16 patients undergoing cardiac
surgery (nonfailing atrial tissue). In both specimen
types, there was a dose-dependent effect of decreased
isometric twitch force with pantoprazole exposure and
partial reversibility after drug washout. This effect was not
mediated by changes in pH (related to H+/K+ inhibition)
but seemed to be mediated by impaired calcium uptake
and reduced myofilament responsiveness. At very high
concentrations of pantoprazole there was near complete
inhibition of cardiac contractility and these effects seemed
to occur within minutes.
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Given the widespread use of these medications in routine
clinical practice, it was important to assess if these effects
have clinical relevance. It was expected that based on the
significant underlying cardiovascular disease and cardiac
dysfunction in our study population, these patients would
be at high risk for acute hemodynamic compromise in the
setting of a drug with potential negative chronotropic and
inotropic effects. However, we were unable to demonstrate
any adverse hemodynamic effects immediately after IV PPI
administration.
This study was limited by a small sample size, hetero-
geneity of the patient population, and uncontrolled use of
concomitant medications. Inotropic agents were used in the
majority of patients and their effects may have mitigated
the negative inotropy and contractility seen in vitro. How-
ever, these differences in clinical conditions and variation
in use of inotropic agents reflect real-world intensive care
settings where these drugs are most likely to be used. In
addition, these patients had relatively stable hemodynamics
and inotropic agent doses were not being actively titrated at
the time of data collection. Finally, despite a small sample
size, we calculated a greater than 80% power to detect a
difference in cardiac index of 0.2 L/min/m2 Finally, most
patients were on either an IV or oral PPI prior to enrollment
in the study. Therefore, we cannot rule out a conditioning
effect due to prior exposure.
In conclusion, these data suggest that IV proton pump
inhibitors at currently employed doses do not immediately
impact important hemodynamic parameters and are likely
safe in a high-risk intensive care setting.
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